Clinical Trial Update: A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 1/2 study evaluating the safety of KAND567 in combination with carboplatin in women with recurrent …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Peritoneal Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• KAND567

Snippet

Sponsor: Novakand Pharma AB | Conditions: Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 1, Phase 2 | Status: COMPLETED